XML 50 R40.htm IDEA: XBRL DOCUMENT v3.25.1
SEGMENT REPORTING (Tables)
 3 Months Ended
Mar. 31, 2025
Segment Reporting [Abstract]  
Schedule of Segment Reporting Information, by Segment
The following table presents a summary of the revenues and Adjusted EBITDA of our two operating segments for the three months ended March 31, 2025 and 2024:
Three Months Ended March 31,
(In thousands)20252024
Revenues:
Financial Health$56,133 $53,439 
Patient Care31,075 30,678 
Total revenues87,208 84,117 
Less:
Financial Health expenses:
Cost of sales (excluding depreciation and amortization and stock compensation expense)$27,073 $29,523 
Product development3,109 2,427 
Sales and marketing3,830 4,282 
General and administrative expenses10,840 10,410 
Total Financial Health expenses$44,852 $46,642 
Patient Care expenses:
Cost of sales (excluding depreciation and amortization and stock compensation expense)$12,241 $12,202 
Product development4,930 8,049 
Sales and marketing1,395 2,171 
General and administrative expenses5,559 4,729 
Total Patient Care expenses$24,125 $27,151 
Total expenses$68,977 $73,793 
Adjusted EBITDA by segment:
Financial Health11,281 6,797 
Patient Care6,950 3,527 
Total Adjusted EBITDA$18,231 $10,324 
Schedule of Reconciliation of Net Income from Continuing Operations to Adjusted Income (Loss) from Before Interest, Taxes, Depreciation and Amortization
The following table reconciles net income to Adjusted EBITDA:
Three Months Ended March 31,
(In thousands)20252024
Net income (loss), as reported$459 $(1,854)
Depreciation expense291 400 
Amortization of software development costs3,071 2,742 
Amortization of acquisition-related intangibles3,053 3,127 
Stock-based compensation1,213 800 
Severance and other non-recurring charges2,443 3,844 
Interest expense and other, net3,291 3,899 
Gain on sale of AHT(53)(1,250)
Provision (benefit) for income taxes4,463 (1,384)
Total Adjusted EBITDA$18,231 $10,324